Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination medication containing lansoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori*. Lansoprazole is a proton pump inhibitor (PPI), amoxicillin is a penicillin-class antibiotic, and clarithromycin is a macrolide antibiotic.
## Primary Indications
* Eradication of *Helicobacter pylori* in patients with peptic ulcer disease.
## Adult Dosing
The typical adult regimen is one capsule (containing lansoprazole 30 mg, amoxicillin 500 mg, and clarithromycin 250 mg) taken twice daily for 7 to 14 days. Specific duration depends on local resistance patterns and clinical guidelines.
## Pediatric Dosing
There is limited specific pediatric dosing data for Sompraz HP as a fixed combination. Dosing for individual components would need to be calculated based on age and weight, with careful consideration of antibiotic choice and duration due to *H. pylori* treatment complexities in children.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment for the combination product is established. However, dose adjustments for amoxicillin and clarithromycin may be necessary in severe renal impairment.
* **Hepatic Impairment:** No specific dose adjustment for the combination product is established. Caution is advised, particularly with clarithromycin.
## Contraindications
* Hypersensitivity to lansoprazole, amoxicillin, clarithromycin, or any component of the formulation.
* History of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use.
* Hypersensitivity to penicillins, cephalosporins, or other beta-lactam antibiotics.
* Patients with a known history of QT prolongation or ventricular arrhythmias.
* Concomitant use with cisapride, pimozide, or other drugs known to prolong the QT interval.
## Adverse Effects
Common adverse effects include diarrhea, nausea, vomiting, abdominal pain, headache, dysgeusia (altered taste), and rash. More serious adverse effects may include severe allergic reactions, *Clostridioides difficile*-associated diarrhea, hepatotoxicity, and QT prolongation.
## Key Drug Interactions
* **Lansoprazole:** May decrease the absorption of drugs requiring an acidic environment (e.g., ketoconazole, itraconazole, iron salts). May increase levels of some drugs metabolized by CYP3A4.
* **Clarithromycin:** Potent inhibitor of CYP3A4, can increase serum concentrations of drugs like simvastatin, lovastatin, carbamazepine, theophylline, and warfarin. Risk of additive QT prolongation with other QT-prolonging agents.
* **Amoxicillin:** May decrease the efficacy of oral contraceptives.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Assess for diarrhea and consider *C. difficile* testing if it develops.
* Monitor liver function tests, especially with prolonged use or in patients with hepatic impairment.
* Evaluate for signs of QT prolongation if risk factors are present.
## Clinical Pearls
* Treatment duration should be guided by local resistance patterns and clinical guidelines to optimize eradication rates and minimize resistance.
* Ensure patients complete the full course of therapy as prescribed.
* Consider taking with food to minimize gastric upset.
* Educate patients on potential side effects and when to seek medical attention.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and relevant clinical guidelines for the most current and complete drug information, as recommendations may vary based on local protocols and individual patient factors.
